Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions

M. Skurlova, K. Holubova, L. Kleteckova, T. Kozak, H. Kubova, J. Horacek, K. Vales

. 2024 ; 44 (1) : 5-22. [pub] 20230602

Language English Country United States

Document type Journal Article, Review

Grant support
AZV 16-29857A Ministry of Health of the Czech Republic
LO1611 MEYS

Cancer treatment brings about a phenomenon not fully clarified yet, termed chemobrain. Its strong negative impact on patients' well-being makes it a trending topic in current research, interconnecting many disciplines from clinical oncology to neuroscience. Clinical and animal studies have often reported elevated concentrations of proinflammatory cytokines in various types of blood cancers. This inflammatory burst could be the background for chemotherapy-induced cognitive deficit in patients with blood cancers. Cancer environment is a dynamic interacting system. The review puts into close relationship the inflammatory dysbalance and oxidative/nitrosative stress with disruption of the blood-brain barrier (BBB). The BBB breakdown leads to neuroinflammation, followed by neurotoxicity and neurodegeneration. High levels of intracellular reactive oxygen species (ROS) induce the progression of cancer resulting in increased mutagenesis, conversion of protooncogenes to oncogenes, and inactivation of tumor suppression genes to trigger cancer cell growth. These cell alterations may change brain functionality, as well as morphology. Multidrug chemotherapy is not without consequences to healthy tissue and could even be toxic. Specific treatment impacts brain function and morphology, functions of the immune system, and metabolism in a unique mixture. In general, a chemo-drug's effects on cognition in cancer are not direct and/or in-direct, usually a combination of effects is more probable. Last but not least, chemotherapy strongly impacts the immune system and could contribute to BBB disruption. This review points out inflammation as a possible mechanism of brain damage during blood cancers and discusses chemotherapy-induced cognitive impairment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000164
003      
CZ-PrNML
005      
20240213093008.0
007      
ta
008      
240109s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/med.21977 $2 doi
035    __
$a (PubMed)37265248
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Skurlova, M $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
245    10
$a Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions / $c M. Skurlova, K. Holubova, L. Kleteckova, T. Kozak, H. Kubova, J. Horacek, K. Vales
520    9_
$a Cancer treatment brings about a phenomenon not fully clarified yet, termed chemobrain. Its strong negative impact on patients' well-being makes it a trending topic in current research, interconnecting many disciplines from clinical oncology to neuroscience. Clinical and animal studies have often reported elevated concentrations of proinflammatory cytokines in various types of blood cancers. This inflammatory burst could be the background for chemotherapy-induced cognitive deficit in patients with blood cancers. Cancer environment is a dynamic interacting system. The review puts into close relationship the inflammatory dysbalance and oxidative/nitrosative stress with disruption of the blood-brain barrier (BBB). The BBB breakdown leads to neuroinflammation, followed by neurotoxicity and neurodegeneration. High levels of intracellular reactive oxygen species (ROS) induce the progression of cancer resulting in increased mutagenesis, conversion of protooncogenes to oncogenes, and inactivation of tumor suppression genes to trigger cancer cell growth. These cell alterations may change brain functionality, as well as morphology. Multidrug chemotherapy is not without consequences to healthy tissue and could even be toxic. Specific treatment impacts brain function and morphology, functions of the immune system, and metabolism in a unique mixture. In general, a chemo-drug's effects on cognition in cancer are not direct and/or in-direct, usually a combination of effects is more probable. Last but not least, chemotherapy strongly impacts the immune system and could contribute to BBB disruption. This review points out inflammation as a possible mechanism of brain damage during blood cancers and discusses chemotherapy-induced cognitive impairment.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    12
$a kognitivní porucha po chemoterapii $x metabolismus $x patologie $7 D000084202
650    12
$a nádory $x farmakoterapie $7 D009369
650    12
$a hematologické nádory $x metabolismus $x patologie $7 D019337
650    _2
$a mozek $x metabolismus $7 D001921
650    _2
$a imunitní systém $7 D007107
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Holubova, K $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a Kleteckova, L $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000274992757
700    1_
$a Kozak, T $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kubova, H $u Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Horacek, J $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a Vales, K $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
773    0_
$w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 44, č. 1 (2024), s. 5-22
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37265248 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093006 $b ABA008
999    __
$a ok $b bmc $g 2049072 $s 1209858
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 44 $c 1 $d 5-22 $e 20230602 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
GRA    __
$a AZV 16-29857A $p Ministry of Health of the Czech Republic
GRA    __
$a LO1611 $p MEYS
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...